Recombinant human erythropoietin might induce strawberry haemangiomas in very‐low‐birthweight preterm infants

Zaffanello, Marco; Franchini, Massimo; Rugolotto, Simone

doi:10.1111/j.1651-2227.2003.tb00511.x

Cited by 12 publications

(4 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The haemangiomas in this neonate were multiple, shortly after starting rEPO. Similarly, rEPO was found to cause the development of haemangiomas in three preterm neonates after 3 or 4 weeks administration with rEPO (Zaffanello et al, 2003). However, haemangioma is the most common benign neoplasm of infancy (Chiller et al, 2002).…”

Section: Haemangiomamentioning

confidence: 95%

Erythropoietin for neonatal brain injury: opportunity and challenge

Xiong

et al. 2011

Intl J of Devlp Neuroscience

View full text Add to dashboard Cite

Neonatal brain injury, caused by perinatal hypoxia-ischemia and extreme prematurity, remains a great challenge for prevention and treatment. There is no effective treatment for term hypoxic-ischemic encephalopathy (HIE) except hypothermia which by itself does not afford complete neuroprotection. Erythropoietin (EPO), a pleiotropic cytokine, has neuroprotective effects in a series of neonatal experimental models and recent clinical trials of HIE. However, the mechanisms, dosing, and the toxicity of EPO in these settings are inconsistently reported. This review will focus on the possible mechanisms, recent clinical advances and potential complications of EPO used in research and the clinic. In addition, optimal dose and administrative routes of EPO, and novel EPO mimetics will be discussed.

show abstract

Section: Haemangiomamentioning

confidence: 95%

Erythropoietin for neonatal brain injury: opportunity and challenge

Xiong

et al. 2011

Intl J of Devlp Neuroscience

View full text Add to dashboard Cite

show abstract

“…98,99,[101][102][103][104] In one retrospective study, an increased risk of cutaneous hemangiomas was reported with Epo exposure in preterm infants, but, as cutaneous hemangiomas are common in preterm infants, a causal relationship has not been established. 83,[105][106][107][108] There are theoretical concerns regarding clotting abnormalities in infants treated with both Epo and therapeutic hypothermia. Hypothermia has negative effects on hemostasis and leads to increased risk of disseminated intravascular coagulation.…”

Section: Epo Dosing and Adverse Effectsmentioning

confidence: 99%

The potential of erythropoietin to treat asphyxia in newborns

Pet¹,

Juul

2014

RRN

View full text Add to dashboard Cite

Perinatal asphyxia is a cause of significant neonatal morbidity worldwide. Lack of oxygenation and perfusion to the neonatal brain leads to energy failure and cell death. Currently, therapeutic hypothermia is the standard of care for term infants with hypoxicischemic encephalopathy, but as it has shown only modest effects on survival and morbidity, additional neuroprotective agents are needed. Erythropoietin has been extensively studied as a neuroprotective agent for infants who suffer a hypoxic-ischemic brain injury. It has multiple mechanisms of action, in both preventing cell death and promoting tissue repair. Studies have progressed over time from in vitro to in vivo studies, first in animals and now in humans, with several Phase I/II trials completed and Phase III trials underway. As therapeutic hypothermia has become the standard of care in treating term infants with hypoxic-ischemic encephalopathy, studies must now evaluate other neuroprotective agents, including erythropoietin, used in concert with therapeutic hypothermia. Erythropoietin has shown promise as a neuroprotective agent in animal and human models, both alone and together with hypothermia.

show abstract

“…Two case reports have previously suggested a potential correlation between erythropoietin treatment and the development of haemangiomas in premature neonates 11 12. Erythropoietin is a well-known treatment for anaemia of prematurity,13 and stimulates erythropoiesis as well as angiogenesis 14 15.…”

Section: Introductionmentioning

confidence: 99%